Provided by Tiger Trade Technology Pte. Ltd.

CARSGEN-B

12.600
+0.1501.20%
Volume:2.95M
Turnover:36.66M
Market Cap:7.48B
PE:-71.08
High:12.750
Open:12.680
Low:12.050
Close:12.450
52wk High:28.600
52wk Low:10.870
Shares:594.00M
HK Float Shares:594.00M
Volume Ratio:1.43
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.177
ROE:-9.57%
ROA:-8.91%
PB:5.82
PE(LYR):-71.08
PS:46.91

Loading ...

CARsgen Therapeutics - Nmpa Approves Satricabtagene Autoleucel for Advanced Gastric/Gastroesophageal Cancer

THOMSON REUTERS
·
Jun 22

Hong Kong Shares Surge as CARSGEN-B Achieves Landmark Approval for First Solid Tumor CAR-T Therapy

Stock News
·
Jun 22

China approves CARsgen Therapeutics satricabtagene autoleucel 'satri-cel' injection

Reuters
·
Jun 22

How Early Allogeneic CAR T Results At CARsgen (SEHK:2171) Have Changed Its Investment Story

Simply Wall St.
·
Jun 19

CARsgen Therapeutics Holdings (SEHK:2171) Stock Looks Rich Even After New CAR T Data

Simply Wall St.
·
Jun 16

Shares of CARSGEN-B Surge Over 5% Following EHA Poster Presentations for CT0596 and CT1190B

Stock News
·
Jun 15

CARsgen releases fresh EHA data on allogeneic CAR-T candidates CT0596 and CT1190B; Phase Ib studies targeted for 2026

Bulletin Express
·
Jun 15

CarsGen-B Showcases Clinical Data for CT0596 and CT1190B at EHA 2026 Congress

Stock News
·
Jun 15

CARsgen presents updated EHA data from CT0596 allogeneic BCMA CAR-T study in relapsed/refractory multiple myeloma

Reuters
·
Jun 15

Movement Alert|CARsgen Therapeutics Rises 5.72% in Regular Trading, In Vivo CAR-T Sector Momentum Fuels Rally

Market Focus
·
Jun 10

CARsgen issues 23.73 million new shares in May; total share count rises 4.16 %, public float intact

Bulletin Express
·
Jun 04

Movement Alert|CARsgen Therapeutics-B Declines 5.14% in Regular Trading, Discounted Placement Dilution and Biotech Sector Weakness Continue to Pressure Shares

Market Focus
·
Jun 02

Movement Alert|CARsgen Therapeutics-B Declines 5.02% in Regular Trading, Discounted Placement Dilution and Institutional Selling Continue to Pressure Shares

Market Focus
·
Jun 01

Long-Term Analysis of CT041 (Satricabtagene Autoleucel) in Advanced Gastric Cancer Presented at 2026 ASCO Annual Meeting

Stock News
·
Jun 01

Long-Term Follow-up Results of CARsgen's Satri-Cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 Asco Annual Meeting

THOMSON REUTERS
·
Jun 01

CARsgen presents long-term ASCO data on satri-cel sequential therapy in advanced gastric cancer subgroup analysis

Reuters
·
Jun 01

Movement Alert|CARsgen Therapeutics Rises 5.47% in Regular Trading, Biotech Sector Rally and Solid Tumor CAR-T Milestone Boost Sentiment

Market Focus
·
May 29

Movement Alert|CARsgen Therapeutics-B Declines 5.19% in Regular Trading, Dilutive Impact of Discounted Placement Continues to Pressure Stock

Market Focus
·
May 28

CARsgen Therapeutics boosts share capital by 4.15% through HKD 19.84 placement and option exercises

Bulletin Express
·
May 26

CARSGEN-B (02171) Finalizes Placement of 23.7 Million Shares via Top-Up Offering, Raising Approximately HK$462 Million Net

Stock News
·
May 26